Nanjing Daoqun received marketing authorization for Oseltamivir Phosphate Capsules from the U.S. Food and Drug Administration (hereinafter referred to as "FDA") on October 31st. This milestone signifies that the Oseltamivir Phosphate Capsules developed by Nanjing Daoqun are qualified for marketing and sales in the United States, effectively aiding the company in expanding its presence in the international market.
Basic Information of the Medication
Drug Name: Oseltamivir Phosphate Capsules
Indications:
For the treatment of influenza A and B in adults and children 1 year of age and older (Oseltamivir Phosphate is effective in treating both types of influenza). It should be used within 48 hours of the onset of symptoms.
For the prevention of influenza A and B in adults and adolescents 13 years of age and older.
Dosage Form: Capsules
Specifications: 75mg, 30mg
Marketing Authorization Holder: Nanjing Daoqun Pharmaceutical Research and Development Co., Ltd.
Manufacturing Company: Shandong Xinhua Pharmaceutical Co., Ltd.
Data Source: Mineiwang
Oseltamivir Phosphate is currently marketed in over 60 countries and regions worldwide and is recognized globally as one of the most effective drugs for the prevention and treatment of influenza viruses.
With the large-scale prevalence of influenza in recent years, the market demand for Oseltamivir has significantly increased. According to Miniwang data, the total market capacity for Oseltamivir oral products in hospitals and chains in China in 2023 was 8 billion yuan.
After the successful development of Daoqun Oseltamivir Phosphate Capsules, applications for generic drugs were submitted in China and the United States, and marketing authorization was granted by the National Medical Products Administration in June 2024; on October 31, 2024, marketing authorization was received from the U.S. Food and Drug Administration.
As the fifth self-developed drug approved by our company, Oseltamivir Phosphate is also recognized globally as one of the most effective drugs for the prevention and treatment of influenza A and B.
Moving forward, Daoqun will continue to invest in product research and innovation, expand into foreign markets, and provide high-quality medicines for patients worldwide.
Collaboration Opportunities Available, Please Contact: 025-8563 7330
About Daoqun Group
Established in 2008, Daoqun Group is headquartered in East China with a business scope encompassing pharmaceutical research and development, sales of medical drugs and devices, and the Internet Plus Healthcare sector. The group's reach spans over 20 provinces including Jiangsu, Zhejiang, and Shanghai, with over 3000 medical institutions and more than 35,000 healthcare professionals in long-term and stable academic cooperation, providing health services to more than 3 million patients.
Adhering to the corporate mission of "Supporting Healthcare and Guarding Health," Daoqun combines innovation with experience to launch multiple self-developed drugs. The company will actively deepen cooperation with industry partners, strive to promote the development of high-quality domestic medicines, and contribute more to the advancement of the healthcare industry.